Vaidehi Kaza1, Chengsong Zhu2, Leying Feng2, Fernando Torres3, Srinivas Bollineni3, Manish Mohanka3, Amit Banga3, John Joerns3, T Mohanakumar4, Lance S Terada3, Quan-Zhen Li5. 1. Division of Pulmonary Critical Care, University of Texas Southwestern Medical Center, Dallas, TX 75390-8814, United States of America. Electronic address: Vaidehi.kaza@utsouthwestern.edu. 2. Department of Immunology, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of America. 3. Division of Pulmonary Critical Care, University of Texas Southwestern Medical Center, Dallas, TX 75390-8814, United States of America. 4. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States of America. 5. Department of Immunology, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States of America. Electronic address: quan.li@utsouthwestern.edu.
Abstract
BACKGROUND: Primary graft Dysfunction (PGD) results in significant mortality and morbidity after lung transplantation (LT). The objective of this study was to evaluate if pre-existing antibodies to self-antigens in sera of LT recipients are associated with PGD. METHODS: The serum profiles of IgG and IgA autoantibodies were analyzed using a customized proteomic microarray bearing 124 autoantigens. Autoantibodies were analyzed using Mann-Whitney U test or Fisher exact test. The association of the autoantibodies with clinical phenotypes and survival was analyzed by Kaplan-Meier Survival Analysis. Receiver operating curve characteristics (ROC) were calculated to evaluate the predictive value of the autoantibodies for PGD. RESULTS: 51 patients were included in this study. Autoantigen microarray analysis on the pre-transplantation samples identified 17 IgA and 3 IgG autoantibodies which were significantly higher in recipients who developed PGD compared to those who did not (adjusted p < .05 and fold change>1.5). 6 IgA Abs were significantly associated with survival. Taken as a panel, an elevation of 6 IgA Abs had significant predictive value for PGD. Area under the curve value for the panel was 0.9413 for PGD with ROC analysis. Notably, 6 of the 17 IgA autoantigen targets are belong to proteoglycan family of extracellular matrix proteins. CONCLUSION: Pre-existing IgG and IgA autoantibodies in LT patients correlate with PGD and with survival in a single center, small cohort of lung transplant recipients. Further validation is needed to confirm the findings in the study. Published by Elsevier B.V.
BACKGROUND:Primary graft Dysfunction (PGD) results in significant mortality and morbidity after lung transplantation (LT). The objective of this study was to evaluate if pre-existing antibodies to self-antigens in sera of LT recipients are associated with PGD. METHODS: The serum profiles of IgG and IgA autoantibodies were analyzed using a customized proteomic microarray bearing 124 autoantigens. Autoantibodies were analyzed using Mann-Whitney U test or Fisher exact test. The association of the autoantibodies with clinical phenotypes and survival was analyzed by Kaplan-Meier Survival Analysis. Receiver operating curve characteristics (ROC) were calculated to evaluate the predictive value of the autoantibodies for PGD. RESULTS: 51 patients were included in this study. Autoantigen microarray analysis on the pre-transplantation samples identified 17 IgA and 3 IgG autoantibodies which were significantly higher in recipients who developed PGD compared to those who did not (adjusted p < .05 and fold change>1.5). 6 IgA Abs were significantly associated with survival. Taken as a panel, an elevation of 6 IgA Abs had significant predictive value for PGD. Area under the curve value for the panel was 0.9413 for PGD with ROC analysis. Notably, 6 of the 17 IgA autoantigen targets are belong to proteoglycan family of extracellular matrix proteins. CONCLUSION: Pre-existing IgG and IgA autoantibodies in LT patients correlate with PGD and with survival in a single center, small cohort of lung transplant recipients. Further validation is needed to confirm the findings in the study. Published by Elsevier B.V.
Authors: Joshua M Diamond; James C Lee; Steven M Kawut; Rupal J Shah; A Russell Localio; Scarlett L Bellamy; David J Lederer; Edward Cantu; Benjamin A Kohl; Vibha N Lama; Sangeeta M Bhorade; Maria Crespo; Ejigayehu Demissie; Joshua Sonett; Keith Wille; Jonathan Orens; Ashish S Shah; Ann Weinacker; Selim Arcasoy; Pali D Shah; David S Wilkes; Lorraine B Ware; Scott M Palmer; Jason D Christie Journal: Am J Respir Crit Care Med Date: 2013-01-10 Impact factor: 21.405
Authors: Fu Jun Li; Ranu Surolia; Huashi Li; Zheng Wang; Tejaswini Kulkarni; Gang Liu; Joao A de Andrade; Daniel J Kass; Victor J Thannickal; Steven R Duncan; Veena B Antony Journal: J Immunol Date: 2017-07-28 Impact factor: 5.426
Authors: Arianne M Brandsma; Sina Bondza; Mitchell Evers; Rosanne Koutstaal; Maaike Nederend; J H Marco Jansen; Thies Rösner; Thomas Valerius; Jeanette H W Leusen; Toine Ten Broeke Journal: Front Immunol Date: 2019-04-11 Impact factor: 7.561
Authors: Alexander McQuiston; Amir Emtiazjoo; Peggi Angel; Tiago Machuca; Jason Christie; Carl Atkinson Journal: Front Immunol Date: 2021-08-11 Impact factor: 7.561
Authors: Daniel R Calabrese; Emily Aminian; Benat Mallavia; Fengchun Liu; Simon J Cleary; Oscar A Aguilar; Ping Wang; Jonathan P Singer; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Mary Nakamura; Lewis L Lanier; Mark R Looney; John R Greenland Journal: J Clin Invest Date: 2021-02-01 Impact factor: 14.808